series-a
Stage
1
Investors
About
AIS Biotech develops glycomimetic anti-infective biotherapies that mimic host-cell sugar receptors to neutralize pathogens, primarily targeting influenza and other infectious diseases using a scalable glycobiotechnology platform.
Explore AIS Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.